|
|
 Previous Article | Table of Contents | Next Article 
Effects of recombinant human interleukin-3 on human hematopoietic
progenitor and precursor cells in vivo
OG Ottmann, A Ganser, G Seipelt, M Eder, G Schulz and D Hoelzer
Department of Hematology, University of Frankfurt, FRG.
DNA-synthesis rates and concentrations of bone marrow (BM) and peripheral
blood (PB) progenitor cells were studied in 22 patients treated with
recombinant human interleukin-3 (rhIL3) as part of a clinical phase I/II
study. Recombinant hIL3 at doses of 60 to 500 micrograms/m2 was
administered by subcutaneous bolus injection for 15 days to 13 patients
with solid tumors and preserved hematopoietic function and to nine patients
with bone marrow failure, including five with myelodysplastic syndromes.
Following treatment with rhIL3, the percentage of actively cycling BM
erythroid (BFU-E) and multilineage (CFU-GEMM) progenitors in patients with
preserved hematopoietic function increased from 16% to 36% (P less than
.05) and from 10% to 40% (P less than .01), respectively. The DNA-synthesis
rates of early and late granulocyte macrophage progenitor cells increased
from 11% to 26% (CFU-GM day 14; P less than .02) and from 13% to 30%
(CFU-GM day 7; P less than .05). There was an increase in BM cellularity
from 37% to 58%, and of the myeloid to erythroid ratio from 1.4 to 3.2,
while the concentration of marrow progenitors on a per cell basis was
unchanged or slightly decreased. The frequencies of blast cells in the BM
were unchanged. Mean levels of PB CFU-GM day 14 and CFU-GEMM were 100% and
72% above baseline values after 7 days of rhIL3 but only 25% and 28% above
initial levels at the end of treatment. Peripheral blood BFU-E were reduced
in the majority of patients with normal marrow after both 7 and 15 days of
rhIL3. No augmentation of circulating BFU-E and CFU- GEMM was seen in 5
patients with MDS who had few or no PB BFU-E or CFU- GEMM initially. Total
leukocyte, neutrophil, and eosinophil counts increased significantly (P
less than .01) in 21 of 22 patients with a peak response after a median of
13 days of rhIL3. While a small increase in reticulocytes was not
accompanied by an elevation of the hemoglobin or hematocrit, platelet
counts increased by 50% in patients with preserved marrow function. Thus,
rhIL3 induces a multilineage response in vivo, apparently by stimulating
proliferation of multipotential and lineage-restricted progenitors. It
remains to be determined whether this is due to direct or indirect effects
on the progenitor cells.
Volume 76,
Issue 8,
pp. 1494-1502,
10/15/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. F. DiPersio, M. W. Schuster, C. N. Abboud, J. N. Winter, V. R. Santos, D. M. Collins, J. W. Sherman, and C. M. Baum
Mobilization of Peripheral-Blood Stem Cells by Concurrent Administration of Daniplestim and Granulocyte Colony-Stimulating Factor in Patients With Breast Cancer or Lymphoma
J. Clin. Oncol.,
July 14, 2000;
18(14):
2762 - 2771.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ballestrero, F. Ferrando, A. Garuti, P. Basta, R. Gonella, P. Stura, G. S. Mela, M. Sessarego, M. Gobbi, and F. Patrone
Comparative Effects of Three Cytokine Regimens After High-Dose Cyclophosphamide: Granulocyte Colony-Stimulating Factor, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), and Sequential Interleukin-3 and GM-CSF
J. Clin. Oncol.,
April 1, 1999;
17(4):
1296 - 1296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.G. Begley, R. Basser, R. Mansfield, B. Thomson, W.R.L. Parker, J. Layton, B. To, J. Cebon, W.P. Sheridan, R.M. Fox, et al.
Enhanced Levels and Enhanced Clonogenic Capacity of Blood Progenitor Cells Following Administration of Stem Cell Factor Plus Granulocyte Colony-Stimulating Factor to Humans
Blood,
November 1, 1997;
90(9):
3378 - 3389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Papayannopoulou, B. Nakamoto, R. G. Andrews, S. D. Lyman, and M. Y. Lee
In Vivo Effects of Flt3/Flk2 Ligand on Mobilization of Hematopoietic Progenitors in Primates and Potent Synergistic Enhancement With Granulocyte Colony-Stimulating Factor
Blood,
July 15, 1997;
90(2):
620 - 629.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L.B. To, D.N. Haylock, P.J. Simmons, and C.A. Juttner
The Biology and Clinical Uses of Blood Stem Cells
Blood,
April 1, 1997;
89(7):
2233 - 2258.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K.W. Lie and L. B. To
Peripheral Blood Stem Cells: Transplantation and Beyond
Oncologist,
February 1, 1997;
2(1):
40 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
